Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s refuse-to-file letter for Firdapse in two ultra-rare neuromuscular disorders does not make judgments about the drug’s safety or efficacy, says Catalyst.
You may also be interested in...
Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
In retrospect, the European Society for Medical Oncology meeting was a showcase for pivotal trial data included in a burst of targeted therapy new drug applications, and more drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study
The latest drug development news and highlights from our FDA Performance Tracker.